Ani Pharmaceuticals (ANIP) Enterprise Value (2013 - 2026)

Ani Pharmaceuticals has disclosed Enterprise Value across 14 years of filings, most recently posting $1.6 billion for Q2 2026.

• In Q2 2026, Enterprise Value rose 30.32% year-over-year to $1.6 billion; the TTM figure through Jun 2026 stood at $1.6 billion (up 30.32% YoY), while the FY2025 annual figure was $1.5 billion, up 45.78% from the prior year.
• Enterprise Value came in at $1.6 billion for Q2 2026 at Ani Pharmaceuticals, up from $1.5 billion in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of $1.9 billion in Q3 2025 to a low of $404.4 million in Q1 2022.
• Average Enterprise Value over 5 years is $1.1 billion, with a median of $1.1 billion recorded in 2024.
• Year-over-year, Enterprise Value retreated 7.14% in 2022 and surged 107.51% in 2023.
• Over 5 years, Enterprise Value stood at $650.8 million in 2022, then soared by 41.67% to $922.0 million in 2023, then grew by 10.84% to $1.0 billion in 2024, then jumped by 45.78% to $1.5 billion in 2025, then increased by 8.35% to $1.6 billion in 2026.
• Per Business Quant data, the three most recent Enterprise Value figures were $1.6 billion in Q2 2026, $1.5 billion in Q1 2026, and $1.5 billion in Q4 2025.